论文部分内容阅读
目的:分析应用单药奈达铂同期放化疗方式对局部晚期鼻咽癌患者进行治疗的临床效果。方法:选择2011年11月-2012年11月在梧州市红十字会医院接受治疗的86例局部晚期鼻咽癌患者随机平分为对照组、观察组各43例。对照组患者给予顺铂同期放化疗进行治疗,观察组患者给予奈达铂同期放化疗治疗,并对临床治疗效果进行比较分析。结果:对照组、观察组出现3级以上急性治疗毒性反应分别为2.33%、4.65%,2年期间患者总生存率分别为83.72%、79.07%,2年无局部区域复发生存率分别93.02%、86.05%,组间比较,差异无统计学意义(P>0.05)。结论:应用单药奈达铂同期放化疗对局部晚期鼻咽癌患者进行治疗所取得的效果与应用顺铂进行治疗所取得的效果相似,不良反应也较少,患者耐受性好。
Objective: To analyze the clinical effect of single-drug Nedaplatin concurrent chemoradiotherapy on patients with locally advanced nasopharyngeal carcinoma. Methods: From November 2011 to November 2012, 86 patients with locally advanced nasopharyngeal carcinoma treated in Wuzhou Red Cross Hospital were randomly divided into control group and observation group of 43 cases. Patients in the control group were treated with cisplatin concurrently with radiotherapy and chemotherapy while patients in the observation group were treated with concurrent chemotherapy and radiotherapy with nedaplatin. The clinical effects were compared and analyzed. Results: In the control group and the observation group, the grade 3 acute toxicities were 2.33% and 4.65% respectively. The overall survival rates were 83.72% and 79.07% respectively in 2 years and 93.02% in 2 years without local recurrence, respectively. 86.05%. There was no significant difference between the two groups (P> 0.05). CONCLUSIONS: The effect of single-drug NADTA concurrent chemoradiotherapy on locally advanced nasopharyngeal carcinoma patients is similar to that of cisplatin, with fewer adverse reactions and better tolerability.